Menu
Back to Journals » Vascular Health and Risk Management » Volume 4 » Issue 2
Vascular Health and Risk Management
ISSN: 1178-2048
- View all (1516)
- Volume 20, 2024 (20)
- Volume 19, 2023 (86)
- Volume 18, 2022 (87)
- Volume 17, 2021 (80)
- Volume 16, 2020 (60)
- Volume 15, 2019 (54)
- Volume 14, 2018 (42)
- Volume 13, 2017 (54)
- Volume 12, 2016 (52)
- Volume 11, 2015 (66)
- Volume 10, 2014 (74)
- Volume 9, 2013 (73)
- Volume 8, 2012 (74)
- Volume 7, 2011 (92)
- Volume 6, 2010 (113)
- Volume 5, 2009 (112)
- Volume 4, 2008 (164)
- Volume 3, 2007 (113)
- Volume 2, 2006 (57)
- Volume 1, 2005 (43)
Archive: Volume 4, 2008
A young man with acute dilated cardiomyopathy associated with methylphenidate
Tor-Bjarne Nymark, A Hovland, H Bjørnstad, E W Nielsen
Vascular Health and Risk Management 2008, 4:477-479
Published Date: 11 April 2008
Effect of ramipril on renal function in patients with intermittent claudication
Simon D Hobbs, Martin W Claridge, Antonius BM Wilmink, Donald J Adam, Mark E Thomas, Andrew W Bradbury
Vascular Health and Risk Management 2008, 4:471-475
Published Date: 11 April 2008
Silent cerebral infarction in chronic heart failure: Ischemic and nonischemic dilated cardiomyopathy
Guliz Kozdag, Ercument Ciftci, Dilek Ural, Tayfun Sahin, Macit Selekler, et al
Vascular Health and Risk Management 2008, 4:463-469
Published Date: 11 April 2008
Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women?
Evelyn O Talbott, Jeanne Zborowski, Judy Rager, Juley R Stragand
Vascular Health and Risk Management 2008, 4:453-462
Published Date: 11 April 2008
Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study
Jean-Jacques Mourad, Dulce Lameira, Pierre-Jean Guillausseau
Vascular Health and Risk Management 2008, 4:443-451
Published Date: 11 April 2008
Time-dependent alterations in serum NO concentration after oral administration of L-arginine, L-NAME, and allopurinol in intestinal ischemia/reperfusion
Amalia E Yanni, Eleutherios Margaritis, Nikolaos Liarakos, Alkisti Pantopoulou, Maria Poulakou, et al
Vascular Health and Risk Management 2008, 4:437-441
Published Date: 11 April 2008
Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: A case-cohort study and meta-analyses
Mohammad Hadi Zafarmand, Yvonne T van der Schouw, Diederick E Grobbee, Peter W de Leeuw, Michiel L Bots
Vascular Health and Risk Management 2008, 4:427-436
Published Date: 11 April 2008
Kennedy space center cardiovascular disease risk reduction program evaluation
Kristine S Calderon, Charles Smallwood, David A Tipton
Vascular Health and Risk Management 2008, 4:421-426
Published Date: 11 April 2008
Japanese study to organize proper lifestyle modifications for metabolic syndrome (J-STOP-MetS): Design and method
Masanori Munakata, Hiroki Honma, Mitugu Akasi, Takaharu Araki, Takahiko Kawamura, et al
Vascular Health and Risk Management 2008, 4:415-420
Published Date: 11 April 2008
Preferred drug lists: Potential impact on healthcare economics
Kimberly Ovsag, Sabrina Hydery, Shaker A Mousa
Vascular Health and Risk Management 2008, 4:403-413
Published Date: 11 April 2008
Risk factors for vascular dementia: Hypotension as a key point
Rita Moretti, Paola Torre, Rodolfo M Antonello, Davide Manganaro, Cristina Vilotti, Gilberto Pizzolato
Vascular Health and Risk Management 2008, 4:395-402
Published Date: 11 April 2008
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
Bo Ahrén
Vascular Health and Risk Management 2008, 4:383-394
Published Date: 11 April 2008
Vascular risk factors, cognitve decline, and dementia
E Duron, Olivier Hanon
Vascular Health and Risk Management 2008, 4:363-381
Published Date: 11 April 2008
Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
Byron J Hoogwerf, Krupa B Doshi, Dima Diab
Vascular Health and Risk Management 2008, 4:355-362
Published Date: 11 April 2008
Clinical efficacy and safety of statins in managing cardiovascular risk
Navin K Kapur, Kiran Musunuru
Vascular Health and Risk Management 2008, 4:341-353
Published Date: 11 April 2008
Regadenoson in the detection of coronary artery disease
Christiane Buhr, Mario Gössl, Raimund Erbel, Holger Eggebrecht
Vascular Health and Risk Management 2008, 4:337-340
Published Date: 11 April 2008
Orlistat in the prevention of diabetes in the obese patient
Marcio C Mancini, Alfredo Halpern
Vascular Health and Risk Management 2008, 4:325-336
Published Date: 11 April 2008
Expert review on coronary calcium
Matthew J Budoff, Khawar M Gul
Vascular Health and Risk Management 2008, 4:315-324
Published Date: 11 April 2008
New anticoagulant strategies in ST elevation myocardial infarction: Trials and clinical implications
Conor J McCann, Ian BA Menown
Vascular Health and Risk Management 2008, 4:305-313
Published Date: 11 April 2008
Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
Francesco Chiarelli, Daniele Di Marzio
Vascular Health and Risk Management 2008, 4:297-304
Published Date: 11 April 2008
Early detection and management of the high-risk patient with elevated blood pressure
Cristina Sierra, Alejandro de la Sierra
Vascular Health and Risk Management 2008, 4:289-296
Published Date: 11 April 2008
Management of venous thromboembolism in patients with cancer: role of dalteparin
Lori-Ann Linkins
Vascular Health and Risk Management 2008, 4:279-287
Published Date: 11 April 2008
Combination therapy in cholesterol reduction: focus on ezetimibe and statins
Liliana Grigore, Giuseppe Danilo Norata, Alberico L Catapano
Vascular Health and Risk Management 2008, 4:267-278
Published Date: 11 April 2008